Adrenochrome Monosemicarbazone is a hemostatic agent derived from the oxidation product of epinephrine. It acts as a capillary stabilizer and is primarily used in India for the management of capillary bleeding, particularly in ophthalmic and ENT surgeries, and in conditions involving increased capillary fragility. It is not a systemic coagulant but works by reducing capillary permeability and promoting platelet adhesion at the endothelial level.
Adult: 1 ampoule (40mg) intramuscularly or slow intravenous injection, 1 to 3 times daily as per surgical need. In surgical settings, often given pre-operatively and/or post-operatively.
Note: For IM use: Administer by deep intramuscular injection. For IV use: Administer as a slow intravenous injection over 2-3 minutes. Do not mix with other medications in the same syringe. Inspect solution for particulate matter or discoloration before use.
Adrenochrome Monosemicarbazone stabilizes the capillary wall by interacting with the intercellular cement substance (hyaluronic acid) and reducing abnormal capillary permeability. It does not affect blood coagulation factors, prothrombin time, or platelet count. Its action is primarily on the vascular endothelium, promoting platelet adhesion and reducing the time for capillary hemostasis.
Pregnancy: Category C: Animal reproduction studies have not been conducted. Use only if the potential benefit justifies the potential risk to the fetus. Reserved for serious surgical situations.
Driving: May cause dizziness; patients should be cautioned about driving or operating machinery if they experience this side effect.
| Anticoagulants (Warfarin, DOACs) | Theoretical reduction in efficacy of Adrenochrome. No direct pharmacodynamic interaction, but concurrent use for different bleeding risks requires monitoring. | Moderate |
| Anti-platelet drugs (Aspirin, Clopidogrel) | May antagonize the capillary stabilizing effect of Adrenochrome in controlling oozing. | Moderate |
| Antihypertensives | No significant interaction reported. | Minor |